Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Neuraxis, INC

NRXS · NYSE · CIK 0001933567 · Healthcare · Biotechnology

INSIDER SIGNAL

54.4 / 100

3 buyers · 3 purchase transaction lines · $12.3K gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeLow
RoleModerate
RecencyStrong
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+1.9 / 25
Role+13.0 / 20
Recency+8.5 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ✓ Recent activity · latest purchase 2026-10-08

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Aharon GilDirector
○○○
Carrico Thomas JoesephCRO, CCO, CPO
○●
Carrico Brian AllenChief Executive Officer
○●
Miranda AdrianCMO, SVP Science & Tech
○
Watkins Bradley MitchellDirector
○
Keyser Jane ElizabethDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION76%Largest buyer: Henrichs Timothy Robert · $9.4K
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-10-08–2026-10-08

Roles in the peak window: CRO, CCO, CPO, Chief Executive Officer, Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

54.4 / 100

Latest recorded score

↓ -0.3 ptsversus the previous recorded snapshot
  1. 55.1
  2. 55.0
  3. 54.8
  4. 54.7
  5. 54.4

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

9Purchases
0Sales
15Other Form 4 lines
20SEC filings · 365 days
BUYING3 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER11 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+17.1%
3M
-6.0%
6M
-3.9%
12M
+121.1%

Volatility & liquidity

Volatility
94.6%
Beta
—
Avg daily value
USD 723,019

Valuation

Market cap
USD 84.4M
P/E
—

Fundamentals

Profit margin
-218.5%
ROE
-229.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-12 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
372,805
Previous report
377,067
Avg daily volume
235,996
Days to cover
1.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-08Henrichs Timothy RobertPurchase (P)Common Stock1,937USD 4.84USD 9,375SEC filing ↗
2026-10-08Carrico Thomas JoesephPurchase (P)Common Stock328USD 4.84USD 1,588SEC filing ↗
2026-10-08Carrico Brian AllenPurchase (P)Common Stock268USD 4.84USD 1,297SEC filing ↗
2026-04-01Henrichs Timothy RobertPurchase (P)Common Stock7,593USD 1.96USD 14,882SEC filing ↗
2026-04-01Carrico Thomas JoesephPurchase (P)Common Stock667USD 1.96USD 1,307SEC filing ↗
2026-04-01Carrico Brian AllenPurchase (P)Common Stock8,060USD 1.96USD 15,798SEC filing ↗
2026-02-12Hannasch BrianPurchase (P)Common Stock40,000USD 4.92USD 196,800SEC filing ↗
2026-02-11Hannasch BrianPurchase (P)Common Stock40,000USD 4.65USD 186,000SEC filing ↗
2025-12-23Aharon GilPurchase (P)Common Shares286,138USD 3.52USD 1,007,206SEC filing ↗
2025-07-01Hannasch BrianPurchase (P)Common Stock355,556USD 2.25USD 800,001SEC filing ↗
2025-04-21Hannasch BrianPurchase (P)Common Stock18,065USD 1.73USD 31,252SEC filing ↗

Form 4 evidence

24 transaction lines in the latest 365-day window; 41 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-08Henrichs Timothy RobertPurchase (P)Common Stock1,937USD 4.84USD 9,375SEC filing ↗
2026-10-08Carrico Thomas JoesephPurchase (P)Common Stock328USD 4.84USD 1,588SEC filing ↗
2026-10-08Carrico Brian AllenPurchase (P)Common Stock268USD 4.84USD 1,297SEC filing ↗
Show recent Form 4 evidence (22 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-08Henrichs Timothy RobertPurchase (P)Common Stock1,937USD 4.84USD 9,375SEC filing ↗
2026-10-08Carrico Thomas JoesephPurchase (P)Common Stock328USD 4.84USD 1,588SEC filing ↗
2026-10-08Carrico Brian AllenPurchase (P)Common Stock268USD 4.84USD 1,297SEC filing ↗
2026-08-24Miranda AdrianAward / grant (A)Common Stock199,106USD —USD —SEC filing ↗
2026-08-24Carrico Thomas JoesephAward / grant (A)Common Stock193,678USD —USD —SEC filing ↗
2026-08-24Carrico Brian AllenAward / grant (A)Common Stock199,188USD —USD —SEC filing ↗
2026-08-13Watkins Bradley MitchellAward / grant (A)Common Stock26,073USD 6.28USD 163,738SEC filing ↗
2026-08-13Keyser Jane ElizabethAward / grant (A)Common Stock26,073USD 6.28USD 163,738SEC filing ↗
2026-08-13Ferge Kristin AAward / grant (A)Common Stock31,134USD 6.28USD 195,522SEC filing ↗
2026-08-13Aharon GilAward / grant (A)Common Stock43,930USD 6.28USD 275,880SEC filing ↗
2026-07-29Aharon GilAward / grant (A)Common Stock42,294USD —USD —SEC filing ↗
2026-04-28Aharon GilAward / grant (A)Common Stock234,221USD —USD —SEC filing ↗
2026-04-01Henrichs Timothy RobertPurchase (P)Common Stock7,593USD 1.96USD 14,882SEC filing ↗
2026-04-01Carrico Thomas JoesephPurchase (P)Common Stock667USD 1.96USD 1,307SEC filing ↗
2026-04-01Carrico Brian AllenPurchase (P)Common Stock8,060USD 1.96USD 15,798SEC filing ↗
2026-02-12Hannasch BrianPurchase (P)Common Stock40,000USD 4.92USD 196,800SEC filing ↗
2026-02-11Hannasch BrianPurchase (P)Common Stock40,000USD 4.65USD 186,000SEC filing ↗
2026-01-22Watkins Bradley MitchellAward / grant (A)Common Stock21,598USD 4.63USD 99,999SEC filing ↗
2026-01-22Keyser Jane ElizabethAward / grant (A)Common Stock21,598USD 4.63USD 99,999SEC filing ↗
2026-01-22Ferge Kristin AAward / grant (A)Common Stock21,598USD 4.63USD 99,999SEC filing ↗
2026-01-22Aharon GilAward / grant (A)Common Shares21,598USD 4.63USD 99,999SEC filing ↗
2025-12-23Aharon GilPurchase (P)Common Shares286,138USD 3.52USD 1,007,206SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNRXS
CIK0001933567
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC3845 Electromedical & Electrotherapeutic Apparatus
ExchangeNYSE

Data coverage

Local Form 4 history41 transaction lines from 2023-08-10 to 2026-10-08
11 P purchase lines · 3 S sale lines · 27 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.